QualityStocks would like to highlight Pure Bioscience, Inc. (NASDAQ: PURE), engaged in the discovery, development, and commercialization of bioscience products principally in the United States. The company offers silver dihydrogen citrate (SDC) based antimicrobials. The silver dihydrogen citrate technology is an electrochemical process that allows the generation of ionized silver in the presence of organic acid.
In the company’s news yesterday,
PURE Bioscience announced that testing has been initiated for SDC-based formulas in direct food applications, to determine if they can be effectively used to reduce foodborne pathogens like listeria, E. coli, and salmonella. This new testing program will build on earlier GRAS designation for SDC on food contact.
Stemming from promising results of initial tests at Deibel Laboratories, additional testing at the University of Georgia is now underway using whole lettuce leaves. These and other upcoming tests are intended to optimize specific formulas for intervention steps during food processing programs. As current chemistries aren’t providing the needed overall protection for the food supply, SDC has the potential to dramatically impact food processing and reduce contamination overall when implemented as a 360-degree farm-to-fork solution. SDC has broad spectrum efficacy, does not trigger bacterial resistance, does not add flavor or odors to food products, and is nonhazardous to food industry workers – making it ideally suited for direct food applications.
PURE Bioscience is seeking additional partners to continue the development of SDC in produce and other food processing segments. The company’s objective is to gather and present the necessary data to gain appropriate FDA and EPA regulatory clearances, as well as to demonstrate SDC’s efficacy for the agricultural market and food processing industry.
PURE Bioscience is engaged in the development and marketing of technology-based bioscience products to provide solutions for numerous worldwide health challenges. The company’s proprietary high-efficacy/low-toxicity bioscience technologies – including its silver dihydrogen citrate-based antimicrobials – offer pioneering advances in various markets and are leading the modern global trend toward industry and consumer use of “green” products – simultaneously providing competitive advances in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC stands apart from its competitors in the marketplace due to superior efficacy, reduced toxicity, and bacteria’s inability to form a resistance to it.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
